4DMEDICAL LIMITED (4DX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

4DX - 4DMEDICAL LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.12
Index: ALL-ORDS | ALL-TECH

4DMedical is a global medical technology company specialising in the treatment of lung disease through respitory imaging and analysis. The company has facilities in Melbourne and Los Angeles. It listed on the ASX in 2020.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.45

21 Nov
2024

-0.025

OPEN

$0.48

-5.26%

HIGH

$0.48

808,869

LOW

$0.45

TARGET
$0.925 105.6% upside
OTHER COMPANIES IN THE SAME SECTOR
AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
4DX: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 9.7 - 6.9 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-9.7
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx3.8 M
Book Value Per Share xxxxxxxxxxxxxxx17.3
Net Operating Cash Flow xxxxxxxxxxxxxxx-30.9 M
Net Profit Margin xxxxxxxxxxxxxxx-958.34 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-50.54 %
Return on Invested Capital xxxxxxxxxxxxxxx-47.73 %
Return on Assets xxxxxxxxxxxxxxx-33.79 %
Return on Equity xxxxxxxxxxxxxxx-50.54 %
Return on Total Capital xxxxxxxxxxxxxxx-63.18 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-31.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx4 M
Total Debt xxxxxxxxxxxxxxx5 M
Goodwill - Gross xxxxxxxxxxxxxxx43 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx31 M
Price To Book Value xxxxxxxxxxxxxxx3.01

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx1.2 M
Capex % of Sales xxxxxxxxxxxxxxx31.28 %
Cost of Goods Sold xxxxxxxxxxxxxxx32 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx20 M
Research & Development xxxxxxxxxxxxxxx5 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

02/09/2024

1

Speculative Buy

$0.75

66.67%

4DMedical missed Bell Potter's expectations on revenue in FY24, as the acquisiton of Imbio did not achieve the growth anticipated. The EBIT loss was also larger than forecast.

The broker assesses the future is now more likely to lay with the private sector and had hoped the commercial arrangement with Philips would be signed already, although that remains pending.

The company is also yet to realise material revenue from the CMS reimbursement for XV LVAS and various initiatives with the US Veterans Affairs remain elusive.

Revenue forecasts are reduced materially for FY25/26 and a Speculative Buy rating is retained with the target reduced to $0.75 from $1.10.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -8.10 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -3.40 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

4DX STOCK CHART

FNArena News on 4DX

1
FNArena Corporate Results Monitor – 02-09-2024

Sep 02 2024 - Australia
2
Dr Boreham’s Crucible: 4D Medical

Apr 23 2024 - Small Caps
3
FNArena Corporate Results Monitor – 29-02-2024

Feb 29 2024 - Australia
4
Rudi’s View: February 2024 Is A Blue Sky Affair

Feb 14 2024 - Rudi's View
5
FNArena Corporate Results Monitor – 30-08-2023

Aug 30 2023 - Australia

Latest Medical Equipment & Devices News

1
ResMed’s Bounce-Back Complete

Oct 29 2024 - Australia
2
Dr Boreham’s Crucible: Pro Medicus

Sep 04 2024 - Australia
3
Pro Medicus: Don’t Stop Me Now

Aug 20 2024 - Technicals
4
Dr Boreham’s Crucible: Blinklab

May 20 2024 - Small Caps
5
ResMed Silences The Doubters

Apr 29 2024 - Australia
6
Dr Boreham’s Crucible: 4D Medical

Apr 23 2024 - Small Caps
7
Uptrend Resumed For ResMed

Mar 19 2024 - Technicals
8
Dr Boreham’s Crucible: Cochlear

Feb 28 2024 - Australia
9
Rudi Interviewed: Ongoing Potential In Technology & Growth

Feb 19 2024 - Rudi's View
10
Dr Boreham’s Crucible: Artrya

Feb 15 2024 - Small Caps